Generate Biomedicines, Inc. Common Stock (GENB) Live Share Price, Invest From India

Generate Biomedicines, Inc. Common Stock Stock Performance

as on June 4, 2026 at 6:59 am IST

Day's Low
Day's High
$11.95
Day's Price Range
$12.90
$12.91
7.44%
Downside
-0.08%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$12.91
100.00%
Downside
-100.00%
Upside

Generate Biomedicines, Inc. Common Stock share price movements today

Previous Close: $11.97
Open: $12.15
Volume: 1.0M
Day's Low - High: $11.95 - $12.90

Generate Biomedicines, Inc. Common Stock Historical Returns

1 Month Return: -8.97 %
3 Month Return: + 0.34 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Generate Biomedicines, Inc. Common Stock Stock Fundamentals & Key Indicators

Check Generate Biomedicines, Inc. Common Stock market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.7B

EPS (TTM)

-2.24

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-81.72%

Generate Biomedicines, Inc. Common Stock vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Generate Biomedicines, Inc. Common Stock with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Generate Biomedicines, Inc. Common Stock	NA	$1.7B	NA	NA	0.00%	NA
Revolution Medicines Inc	BUY	$34.8B	401.69%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.5B	94.26%	74.09	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$111.3B	101.32%	26.05	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$63.0B	19.23%	14.66	29.65%	0.58%

Indian Investors' Interest in Generate Biomedicines, Inc. Common Stock Stock

Search interest for Generate Biomedicines, Inc. Common Stock Stock has increased by 1556% in the last 30 days, reflecting an upward trend in search activity.

Time period: May 5, 2026 to June 4, 2026

Change:1556% versus previous 30 day period

Generate Biomedicines, Inc. Common Stock Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2025	Mar 2026
Total Revenue	8	7
Gross Profit	-	3
Operating Income	-48	-64
EBITDA	-	-60
Interest Expense	0	0
Depreciation	3	3
Income Before Tax	-44	-61
Income Tax Expense	-	0
Net Income	-41	-61
Net Profit Margin	-472.73%	-850.58%

Generate Biomedicines, Inc. Common Stock Annual Profit & Loss

All numbers in Millions USD

	Dec 2024	Dec 2025
Total Revenue	20	31
Gross Profit	20	31
Operating Income	-196	-235
EBITDA	-163	-208
Interest Expense	2	1
Depreciation	15	13
Income Before Tax	-181	-222
Income Tax Expense	0	0
Net Income	-173	-203
Net Profit Margin	-849.36%	-636.99%

Generate Biomedicines, Inc. Common Stock Quarterly Cash Flow

All numbers in Millions USD

	Mar 2026
Net Income	-61
Operating Cash Flow	-80
Investing Cash Flow	-252
Financing Cash Flow	371
Change in Cash	160

Generate Biomedicines, Inc. Common Stock Annual Cash Flow

All numbers in Millions USD

	Dec 2025
Net Income	-222
Operating Cash Flow	-200
Investing Cash Flow	116
Financing Cash Flow	28
Change in Cash	-55

Global Institutional Holdings in Generate Biomedicines, Inc. Common Stock

Funds	Holdings
Davern Capital Partners, L.P.	0.46%
Alyeska Investment Group, L.P.	0.39%
UBS Group AG	0.28%
Sphera Funds Management Ltd.	0.14%
ARCH VENTURE CORP	1.52%

See all

Insights on Generate Biomedicines, Inc. Common Stock

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NEGATIVE IMPACT
Price Dip
In the last 7 days, GENB stock has moved down by -8.6%

About Generate Biomedicines, Inc. Common Stock

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.

Organisation	Generate Biomedicines, Inc. Common Stock
Headquarters	101 South Street, Somerville, MA, United States, 02143
Industry	Biotechnology
CEO	Mr. Michael T. Nally M.B.A.
E-voting on shares	Click here to vote

Key Management of Generate Biomedicines, Inc. Common Stock

Name	Title
Mr. Michael T. Nally M.B.A.	CEO & Director
Ms. Beth Grous	Chief People Officer
Dr. Daria Hazuda Ph.D.	Senior Vice President of Discovery Strategy
Dr. Noubar B. Afeyan Ph.D.	Co-founder & Independent Chair of the Board
Dr. Jason E. Silvers J.D., M.D.	President & CFO
Dr. Gevorg Grigoryan Ph.D.	Co-Founder & CTO
Ms. Molly Gibson Ph.D.	Co-Founder
Dr. Aarif Khakoo M.B.A., M.D.	Chief Scientific Officer
Mr. Sean B. W. Martin J.D.	Secretary, Chief Legal Officer & General Counsel
Mr. Sahm Nasseri M.B.A.	Senior Vice President of Business Development & Strategy

FAQs

What is Generate Biomedicines, Inc. Common Stock share price today?

Generate Biomedicines, Inc. Common Stock share price today is $12.91 as on June 4, 2026 at 1:29 am IST at the close of the market. Generate Biomedicines, Inc. Common Stock share today touched a day high of $12.9 and a low of $11.95.

What is the 52 week high and 52 week low for Generate Biomedicines, Inc. Common Stock share?

Generate Biomedicines, Inc. Common Stock share touched a 52 week high of $0 on January 1, 1970 and a 52 week low of $0 on January 1, 1970. Generate Biomedicines, Inc. Common Stock stock price today i.e. June 4, 2026 at 1:29 am IST is closed at $12.91,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Generate Biomedicines, Inc. Common Stock's market capitalisation today?

Generate Biomedicines, Inc. Common Stock market capitalisation is $0.00T as on June 4, 2026 at 1:29 am IST.

How to invest in Generate Biomedicines, Inc. Common Stock Stock (GENB) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Generate Biomedicines, Inc. Common Stock on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Generate Biomedicines, Inc. Common Stock Shares that will get you 0.1162 shares as per Generate Biomedicines, Inc. Common Stock share price of $12.91 per share as on June 4, 2026 at 1:29 am IST.

What is the minimum amount required to buy Generate Biomedicines, Inc. Common Stock Stock (GENB) from India?

Indian investors can start investing in Generate Biomedicines, Inc. Common Stock (GENB) shares with as little as ₹95.695 or $1 (as of June 4, 2026 at 6:45 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in Generate Biomedicines, Inc. Common Stock stock (as per the Rupee-Dollar exchange rate as on June 4, 2026 at 6:45 am IST). Based on Generate Biomedicines, Inc. Common Stock share’s latest price of $12.91 as on June 4, 2026 at 1:29 am IST, you will get 0.7746 shares of Generate Biomedicines, Inc. Common Stock. Learn more about fractional shares .